21st Feb 2007 07:02
Sinclair Pharma PLC21 February 2007 Sinclair Pharma plc announces Dexcel Pharma as new Aloclair(R) distributor in the UK 21 February 2007, Godalming, UK: Sinclair Pharma plc ("Sinclair", SPH:L), theinternational specialty pharmaceutical company, announces that it has signed adeal with Dexcel Pharma to sell its flagship mouth ulcer product, Aloclair(R),in the UK. Until now, in the UK Aloclair has been promoted exclusively to consumers. As aresult of this new deal, Aloclair will now be promoted to dental professionalsas well as consumers. This is considered a key sales driver; Aloclair hashighest market share in the territories where dental professionals are alsotargeted, and can be used to access wider indications such as minor mouthlesions due to dentures or orthodontics. Dexcel will launch Aloclair gel in the UK as well as selling the rinse and spraypresentations. The gel has proven to be the highest-selling and fastest-growingpresentation in most of the 27 territories in which Aloclair has so far beenlaunched and this agreement with Dexcel is a further step to grow the presenceof the brand in the UK. Dexcel Pharma has a turnover in excess of £20m and a significant presence in theUK dental market, where it sells products in periodontitis. Dr Michael Flynn, CEO of Sinclair Pharma, said: "We are very pleased to take this important step through this agreement withDexcel as our UK distributor for Aloclair, which will take the promotion ofAloclair to dental professionals as well as to the general public. We believethat Dexcel's expertise in dental and OTC promotion makes them the ideal partnerfor this product in our important home market." Terry Grigg, Sales and Marketing Director of Dexcel Pharma, added: "Aloclair has excellent market penetration in many territories worldwide, and weare excited about selling it in the UK. The UK dental profession welcomesinnovative products and we believe that Aloclair meets their need for aneffective, easy-to-use product to address the symptoms of mouth ulcers andlesions." Under the terms of the deal announced today, Sinclair will supply AloclairRinse, Gel and Spray to Dexcel, which will be responsible for the marketing anddistribution of the product in the UK, to consumers and dental professionals.Sinclair will receive profit share payments as well as a margin on transferprice. Sales are expected to commence in the next few months, and will meet aneed that has already been generated by four years of OTC promotion in the UK. - ends - For further information please contact: Sinclair Pharma plcDr Michael Flynn, CEO Tel: +44 (0) 1483 410 600Zoe McDougall, Director of Communications Tel: +44 (0) 7973 792 520 UKCapital MS&LMary Clark, Halina Kukula Tel +44 (0)20 7307 5340 GermanyMC ServicesRaimund Gabriel, Hilda Juhasz Tel +49 89 210 228 0 Dexcel PharmaTerry Grigg, Sales and Marketing Director Tel +44 (0) 1327 312 266 Notes to Editors: Sinclair Pharma plc Sinclair Pharma plc is an international specialty pharmaceutical company. Ithas a growing sales and marketing operation that is already present in France,Italy, UK, Spain and Portugal, and a complementary marketing partner networkthat spans more than 65 countries. Sinclair has proven expertise in acquiring or developing commercially attractiveand undervalued products, registering these products and bringing them to marketwithin a short time frame. The company focuses on niche therapeutic areas andits current portfolio includes products for dermatological conditions and oralhealth. Dexcel Pharma Dexcel Pharma Ltd is the UK subsidiary of a significant international companywith strong presences in OTC Markets, Dental Markets and also Branded andGeneric Pharmaceutical markets. Dexcel Pharma has a full programme of productinitiatives in the Dental Market and further details of this developingportfolio will be announced over the coming months. Aloclair Aloclair has marketing clearance in the US and the EU. Sinclair has marketingpartners for the Aloclair range in 66 countries worldwide, including the EU, US,many Latin American countries and China. It has been launched in 27 countriesand is in registration in the remainder of these territories. Approximately 20% of the general population is affected by mouth ulcers, andthey are particularly common in children, women and the over 65s. Aloclair isalready penetrating this market with retail sales of more than £5m in the majorEU countries alone. Aloclair has a novel mode of action, forming a protective coating over the mouthulcer, providing fast and durable pain relief, without stinging on application.There are three presentations; gel, mouth rinse and spray. Other languages For versions of this press release in German, French, Spanish or Japanese pleasecontact [email protected] "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of1995: Some or all of the statements in this document that relate to futureplans, expectations, events, performances and the like are forward-lookingstatements, as defined in the US Private Securities Litigation Reform Act of1995. Actual results of events could differ materially from those described inthe forward- looking statements due to a variety of factors. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Sinclair Pharma